These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10810778)

  • 1. Medical progress and rationing of cardiological services.
    Kreuzer J; Kübler W
    Z Kardiol; 2000; 89 Suppl 4():IV61-7. PubMed ID: 10810778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective].
    Klever-Deichert G; Hinzpeter B; Wendland G; Lauterbach K
    Med Klin (Munich); 2000 Jun; 95(6):305-13. PubMed ID: 10935414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Economic analysis of secondary prevention of coronary heart disease with simvastatin (Zocor) in Germany].
    Obermann K; Mattias Graf ; Schulenburg JM; Mautner GC
    Med Klin (Munich); 1997 Nov; 92(11):686-94. PubMed ID: 9480401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
    Pharoah PD; Hollingworth W
    BMJ; 1996 Jun; 312(7044):1443-8. PubMed ID: 8664620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowering of LDL cholesterol.
    Sniderman AD
    Lancet; 2000 Jan; 355(9199):235. PubMed ID: 10675147
    [No Abstract]   [Full Text] [Related]  

  • 6. [Basic principles of cost-benefit analysis in long-term treatment of risk factors].
    Szucs TD; Gutzwiller F
    Schweiz Med Wochenschr; 1998 Dec; 128(49):1958-64. PubMed ID: 9887476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations.
    Montagne O; Vedel I; Durand-Zaleski I
    Clin Ther; 1999 Nov; 21(11):2027-35. PubMed ID: 10890271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention.
    Am J Manag Care; 1998 Apr; 4(4 Suppl):S185-90. PubMed ID: 10184933
    [No Abstract]   [Full Text] [Related]  

  • 9. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
    Klose G
    Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
    [No Abstract]   [Full Text] [Related]  

  • 10. Health and economic issues in the prevention of coronary artery disease.
    Hogan T
    Am J Cardiol; 1995 Jul; 76(2):140A-142A. PubMed ID: 7604790
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic benefits of aggressive lipid lowering: a managed care perspective.
    McKenney JM; Kinosian B
    Am J Manag Care; 1998 Jan; 4(1):65-74. PubMed ID: 10179907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing the cost-effectiveness of lipid-lowering therapy.
    Jacobson TA; Schein JR; Williamson A; Ballantyne CM
    Arch Intern Med; 1998 Oct; 158(18):1977-89. PubMed ID: 9778197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost and health implications of cholesterol lowering.
    Goldman L; Gordon DJ; Rifkind BM; Hulley SB; Detsky AS; Goodman DW; Kinosian B; Weinstein MC
    Circulation; 1992 May; 85(5):1960-8. PubMed ID: 1572059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Siegel D; Swislocki AL
    JAMA; 1999 Feb; 281(5):417-9. PubMed ID: 9952198
    [No Abstract]   [Full Text] [Related]  

  • 17. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Mason JM; Freemantle N
    JAMA; 1999 Feb; 281(5):415-6; author reply 417-9. PubMed ID: 9952194
    [No Abstract]   [Full Text] [Related]  

  • 18. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
    Shepherd J
    Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost implications of lipid-lowering treatments.
    Reckless JP
    Pharmacoeconomics; 1994 Oct; 6(4):310-23. PubMed ID: 10147467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.